Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study.

Mathias Rummel, N. Niederle, Georg Maschmeyer et al.|Journal of Clinical Oncology|2012

Cited by 39